Apolipoprotein E/ApoE Antibody

Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. The APOE gene is mapped to chromosome 19 in a cluster with APOC1 and APOC2. Defects in apolipoprotein E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 1 application: IF/IHC.

Showing Publications 1 - 2 of 2.

Publications using NB100-1530	Applications	Species
Cipollari, E, Szapary, H J Et al. Correlates and Predictors of Cerebrospinal Fluid Cholesterol Efflux Capacity from Neural Cells, a Family of Biomarkers for Cholesterol Epidemiology in Alzheimer's Disease. J Alzheimers Dis 2020-02-18 [PMID: 32065798] (IF/IHC, Human)	IF/IHC	Human
Dodart JC, Marr RA, Koistinaho M, Gregersen BM, Malkani S, Verma IM, Paul SM. Gene delivery of human apolipoprotein E alters brain A{beta} burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A;102(4):1211-6. 2005-01-25 [PMID: 15657137]

Array NB100-1530

• Apolipoprotein E/ApoE Antibodies
• Apolipoprotein E/ApoE ELISA Kits
• Apolipoprotein E/ApoE Lysate
• Apolipoprotein E/ApoE Protein
• Apolipoprotein E/ApoE Proteins and Enzyme